医学综述
醫學綜述
의학종술
MEDICAL RECAPITULATE
2015年
8期
1432-1435
,共4页
何改平(综述)%张彬(审校)
何改平(綜述)%張彬(審校)
하개평(종술)%장빈(심교)
新型口服抗凝药物%华法林%心房颤动%血栓栓塞
新型口服抗凝藥物%華法林%心房顫動%血栓栓塞
신형구복항응약물%화법림%심방전동%혈전전새
New oral anticoagulants%Warfarin%Atrial fibrillation%Thromboembolism
新型口服抗凝药物（NOAC）通过凝血酶（达比加群酯）或凝血因子Xa（利伐沙班和阿哌沙班）途径预防和治疗血栓。与维生素K抑制剂（如华法林）比较，NOAC优势明显，起效快、代谢迅速、药物相互作用少、药动学预测性好、不需要常规监测凝血功能。近期临床试验证实了 NOAC 预防心房颤动患者卒中和栓塞、骨科手术后静脉血栓栓塞症的安全性和有效性。
新型口服抗凝藥物（NOAC）通過凝血酶（達比加群酯）或凝血因子Xa（利伐沙班和阿哌沙班）途徑預防和治療血栓。與維生素K抑製劑（如華法林）比較，NOAC優勢明顯，起效快、代謝迅速、藥物相互作用少、藥動學預測性好、不需要常規鑑測凝血功能。近期臨床試驗證實瞭 NOAC 預防心房顫動患者卒中和栓塞、骨科手術後靜脈血栓栓塞癥的安全性和有效性。
신형구복항응약물（NOAC）통과응혈매（체비가군지）혹응혈인자Xa（리벌사반화아고사반）도경예방화치료혈전。여유생소K억제제（여화법림）비교，NOAC우세명현，기효쾌、대사신속、약물상호작용소、약동학예측성호、불수요상규감측응혈공능。근기림상시험증실료 NOAC 예방심방전동환자졸중화전새、골과수술후정맥혈전전새증적안전성화유효성。
The new oral anticoagulants(NOAC) target on either thrombin(dabigatran etexilate) or clot-ting factor Xa ( rivaroxaban and apixaban ) for the prevention and treatment of thrombosis .Compared with vitamin K inhibitors ( such as warfarin ) , NOAC have pharmacologic advantages of rapid onset/offset of action,few drug interactions,predictable pharmacokinetics,and no requirement for regular coagulation moni-toring.Recent clinical trials have demonstrated the efficacy and safety of NOAC in preventing and treating stroke in patients with atrial fibrillation and venous thromboembolism as well as venous thromboembolism in patients after hip or knee arthroplasty .
